Source comparison
Tesamorelin Dosage for Cognitive Function: Protocol Comparison
Aged mice (preclinical, J Neuroscience 2021) 1mg/kg 16 weeks Hippocampal neurogenesis (BrdU+ cells) +35% Sustained neurogenesis observed only with chronic dosing. Intermittent protocols showed no benefit Primate model (unpublished, cited in review literature)
This comparison does not assign a generated winner or score.
- Aged mice (preclinical, J Neuroscience 2021)
- 1mg/kg
- 16 weeks
- Hippocampal neurogenesis (BrdU+ cells)
- +35%
- Sustained neurogenesis observed only with chronic dosing. Intermittent protocols showed no benefit
- Primate model (unpublished, cited in review literature)
- 1.5mg daily
- 12 weeks
- Spatial memory (Barnes maze latency)
- +28%
- Memory improvement correlated with IGF-1 elevation, not GH levels
- Human trial (HIV cognitive impairment, AIDS 2020)
- 2mg daily
- 26 weeks
- Executive function (Trail Making Test Part B)
- +32%
- Cognitive gains sustained only during active treatment. Effects reversed 8 weeks post-discontinuation
- Rodent dose-response study (Front Aging Neurosci 2019)
- 0.5mg/kg vs 2mg/kg
- Novel object recognition
- +22% (low dose) vs +18% (high dose)
- Higher doses did not produce greater cognitive benefit and increased glucose intolerance risk